Share
array:25 [ "pii" => "S0300289619301127" "issn" => "03002896" "doi" => "10.1016/j.arbres.2019.03.001" "estado" => "S300" "fechaPublicacion" => "2020-02-01" "aid" => "2123" "copyright" => "SEPAR" "copyrightAnyo" => "2019" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Arch Bronconeumol. 2020;56:76-83" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 150 "formatos" => array:2 [ "HTML" => 72 "PDF" => 78 ] ] "Traduccion" => array:1 [ "en" => array:19 [ "pii" => "S1579212920300100" "issn" => "15792129" "doi" => "10.1016/j.arbr.2019.03.025" "estado" => "S300" "fechaPublicacion" => "2020-02-01" "aid" => "2123" "copyright" => "SEPAR" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Arch Bronconeumol. 2020;56:76-83" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 1 "HTML" => 1 ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Serum Levels of Alpha1-antitrypsin and Their Relationship With COPD in the General Spanish Population" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:3 [ 0 => "en" 1 => "en" 2 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "76" "paginaFinal" => "83" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Niveles séricos de alfa-1 antitripsina y su relación con la EPOC en la población española" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 1 "multimedia" => array:5 [ "identificador" => "fig0015" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => false "mostrarDisplay" => true "figura" => array:1 [ 0 => array:4 [ "imagen" => "fx1.jpeg" "Alto" => 936 "Ancho" => 1333 "Tamanyo" => 103242 ] ] ] ] "autores" => array:3 [ 0 => array:2 [ "autoresLista" => "Sabina Janciauskiene, David S. DeLuca, Miriam Barrecheguren, Tobias Welte, Marc Miravitlles" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Sabina" "apellidos" => "Janciauskiene" ] 1 => array:2 [ "nombre" => "David S." "apellidos" => "DeLuca" ] 2 => array:2 [ "nombre" => "Miriam" "apellidos" => "Barrecheguren" ] 3 => array:2 [ "nombre" => "Tobias" "apellidos" => "Welte" ] 4 => array:2 [ "nombre" => "Marc" "apellidos" => "Miravitlles" ] ] ] 1 => array:2 [ "autoresLista" => "" "autores" => array:1 [ 0 => array:1 [ "colaborador" => "Scientific Committee" ] ] ] 2 => array:2 [ "autoresLista" => "" "autores" => array:1 [ 0 => array:1 [ "colaborador" => "Participating sites and coordinators" ] ] ] ] "resumen" => array:1 [ 0 => array:3 [ "titulo" => "Graphical abstract" "clase" => "graphical" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0015"></elsevierMultimedia></p></span>" ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S0300289619301127" "doi" => "10.1016/j.arbres.2019.03.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289619301127?idApp=UINPBA00003Z" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1579212920300100?idApp=UINPBA00003Z" "url" => "/15792129/0000005600000002/v2_202002112050/S1579212920300100/v2_202002112050/en/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S0300289619301206" "issn" => "03002896" "doi" => "10.1016/j.arbres.2019.03.009" "estado" => "S300" "fechaPublicacion" => "2020-02-01" "aid" => "2131" "copyright" => "SEPAR" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Arch Bronconeumol. 2020;56:84-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 226 "formatos" => array:2 [ "HTML" => 115 "PDF" => 111 ] ] "es" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original</span>" "titulo" => "Perfil social de los pacientes que ingresan por una agudización de EPOC. Un análisis desde una perspectiva de género" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:3 [ 0 => "es" 1 => "es" 2 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "84" "paginaFinal" => "89" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Social Profile of Patients Admitted for COPD Exacerbations. A Gender Analysis" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 1 "multimedia" => array:5 [ "identificador" => "fig0005" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => false "mostrarDisplay" => true "figura" => array:1 [ 0 => array:4 [ "imagen" => "fx1.jpeg" "Alto" => 799 "Ancho" => 1333 "Tamanyo" => 140072 ] ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Sara Fernández-García, Cristina Represas-Represas, Alberto Ruano-Raviña, Mar Mosteiro-Añón, Cecilia Mouronte-Roibas, Alberto Fernández-Villar" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Sara" "apellidos" => "Fernández-García" ] 1 => array:2 [ "nombre" => "Cristina" "apellidos" => "Represas-Represas" ] 2 => array:2 [ "nombre" => "Alberto" "apellidos" => "Ruano-Raviña" ] 3 => array:2 [ "nombre" => "Mar" "apellidos" => "Mosteiro-Añón" ] 4 => array:2 [ "nombre" => "Cecilia" "apellidos" => "Mouronte-Roibas" ] 5 => array:2 [ "nombre" => "Alberto" "apellidos" => "Fernández-Villar" ] ] ] ] "resumen" => array:1 [ 0 => array:3 [ "titulo" => "Graphical abstract" "clase" => "graphical" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0005"></elsevierMultimedia></p></span>" ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1579212919304161" "doi" => "10.1016/j.arbr.2019.03.021" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1579212919304161?idApp=UINPBA00003Z" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289619301206?idApp=UINPBA00003Z" "url" => "/03002896/0000005600000002/v4_202007190708/S0300289619301206/v4_202007190708/es/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0300289619303114" "issn" => "03002896" "doi" => "10.1016/j.arbres.2019.07.009" "estado" => "S300" "fechaPublicacion" => "2020-02-01" "aid" => "2229" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Arch Bronconeumol. 2020;56:74-5" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1043 "formatos" => array:3 [ "EPUB" => 44 "HTML" => 678 "PDF" => 321 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Nuevas perspectivas en infección tuberculosa latente" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "74" "paginaFinal" => "75" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "New Perspectives in Latent Tuberculosis Infection" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Miguel Arias-Guillén, Patricio Escalante, Juan José Palacios Gutiérrez" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Miguel" "apellidos" => "Arias-Guillén" ] 1 => array:2 [ "nombre" => "Patricio" "apellidos" => "Escalante" ] 2 => array:2 [ "nombre" => "Juan José" "apellidos" => "Palacios Gutiérrez" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1579212919304227" "doi" => "10.1016/j.arbr.2019.07.006" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1579212919304227?idApp=UINPBA00003Z" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289619303114?idApp=UINPBA00003Z" "url" => "/03002896/0000005600000002/v4_202007190708/S0300289619303114/v4_202007190708/es/main.assets" ] "asociados" => array:1 [ 0 => array:18 [ "pii" => "S0300289619302856" "issn" => "03002896" "doi" => "10.1016/j.arbres.2019.06.010" "estado" => "S300" "fechaPublicacion" => "2020-02-01" "aid" => "2207" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Arch Bronconeumol. 2020;56:72-3" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 97 "formatos" => array:2 [ "HTML" => 45 "PDF" => 52 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "What Do Alpha-1 Antitrypsin Levels Tell Us About Chronic Inflammation in COPD?" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "72" "paginaFinal" => "73" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "¿Qué nos dicen los niveles de alfa-1 antitripsina sobre la inflamación crónica en EPOC?" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Paul Ellis, Alice Turner" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Paul" "apellidos" => "Ellis" ] 1 => array:2 [ "nombre" => "Alice" "apellidos" => "Turner" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1579212920300094" "doi" => "10.1016/j.arbr.2019.06.015" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1579212920300094?idApp=UINPBA00003Z" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289619302856?idApp=UINPBA00003Z" "url" => "/03002896/0000005600000002/v4_202007190708/S0300289619302856/v4_202007190708/en/main.assets" ] ] "en" => array:21 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Serum Levels of Alpha1-antitrypsin and Their Relationship With COPD in the General Spanish Population" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "76" "paginaFinal" => "83" ] ] "autores" => array:3 [ 0 => array:4 [ "autoresLista" => "Sabina Janciauskiene, David S. DeLuca, Miriam Barrecheguren, Tobias Welte, Marc Miravitlles" "autores" => array:5 [ 0 => array:3 [ "nombre" => "Sabina" "apellidos" => "Janciauskiene" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 1 => array:3 [ "nombre" => "David S." "apellidos" => "DeLuca" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 2 => array:3 [ "nombre" => "Miriam" "apellidos" => "Barrecheguren" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 3 => array:3 [ "nombre" => "Tobias" "apellidos" => "Welte" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 4 => array:4 [ "nombre" => "Marc" "apellidos" => "Miravitlles" "email" => array:1 [ 0 => "miravitlles@vhebron.net" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Department of Respiratory Medicine, Hannover Medical School, Biomedical Research in End-stage and Obstructive Lung Disease Hannover (BREATH), Member of German Centre for Lung Research (DZL), Hannover, Germany" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Pneumology Department, Hospital Universitari Vall d’Hebron/Vall d’Hebron Research Institute (VHIR), CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] 1 => array:2 [ "autoresLista" => "" "autores" => array:1 [ 0 => array:1 [ "colaborador" => "Scientific Committee" ] ] ] 2 => array:2 [ "autoresLista" => "" "autores" => array:1 [ 0 => array:1 [ "colaborador" => "Participating sites and coordinators" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Niveles séricos de alfa-1 antitripsina y su relación con la EPOC en la población española" ] ] "resumenGrafico" => array:2 [ "original" => 1 "multimedia" => array:5 [ "identificador" => "fig0015" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => false "mostrarDisplay" => true "figura" => array:1 [ 0 => array:4 [ "imagen" => "fx1.jpeg" "Alto" => 938 "Ancho" => 1333 "Tamanyo" => 96378 ] ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Alpha1-antitrypsin (AAT) is an acute phase protein, major inhibitor of neutrophil serine proteases like elastase but also considered as a regulatory protein of broad immune and inflammatory responses. Experimental data provide evidence that AAT assists host defences by neutralizing inflammation-induced molecules (such as proteases, cytokines and oxidants), by diminishing the pro-inflammatory responses of circulating leukocytes, and by forestalling endothelial activation.<a class="elsevierStyleCrossRefs" href="#bib0175"><span class="elsevierStyleSup">1,2</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">The clinical importance of AAT is highlighted in individuals with inherited AAT deficiency, who exhibit high risk for developing early-onset pulmonary emphysema and liver disease at any age.<a class="elsevierStyleCrossRef" href="#bib0185"><span class="elsevierStyleSup">3</span></a> Because inherited AAT deficiency is a well-established genetic risk factor for chronic obstructive pulmonary disease (COPD), most of the clinical studies focus on reduced plasma levels and biological activity of AAT protein in cohorts of COPD. Hitherto, less attention given to the levels of plasma AAT in the general population and in COPD patients without inherited AAT deficiency.</p><p id="par0015" class="elsevierStylePara elsevierViewall">Here we used data from the EPI-SCAN, a multicentre, epidemiological study conducted in Spain.<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">4</span></a> Our aim was to determine plasma AAT levels in a cohort of participants diagnosed with COPD, having respiratory symptoms-presence of chronic cough and sputum production but no clinical diagnosis of COPD, and the reference group, those with normal spirometry and without respiratory symptoms, considered healthy persons. We also wanted to evaluate independent predictors of AAT levels including age, lung function measures, smoking, and clinical laboratory data.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Design of the study</span><p id="par0020" class="elsevierStylePara elsevierViewall">The present study is a part of the EPI-SCAN study, which was a multicentre, cross-sectional, population-based, observational study conducted at 11 sites in 10 Spanish cities (Barcelona, Burgos, Córdoba, Huesca, Madrid (two areas), Requena, Sevilla, Oviedo, Vic and Vigo) representing different geographic, climatic and socio-economic regions. The main objective of the study was to investigate the prevalence of COPD in Spain in individuals between 40 and 80 years of age. The protocol of the EPI-SCAN study has been published elsewhere.<a class="elsevierStyleCrossRef" href="#bib0190"><span class="elsevierStyleSup">4</span></a> Fieldwork and all methods have been described previously.<a class="elsevierStyleCrossRef" href="#bib0195"><span class="elsevierStyleSup">5</span></a> The corresponding ethics committees approved the study and all participants gave written informed consent.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Study participants</span><p id="par0025" class="elsevierStylePara elsevierViewall">The final recruited population consisted of 3802 non-institutionalized participants from 40 to 80 years of age. The definition of COPD was a post-bronchodilator FEV1/FVC ratio <0.70. Subjects considered not to have COPD had a post-bronchodilator FEV1/FVC ratio ≥0.70.<a class="elsevierStyleCrossRef" href="#bib0200"><span class="elsevierStyleSup">6</span></a> The blood sample we obtained from all participants classified as having COPD. To avoid excessive testing of the non-COPD population, each study center collected equal number of blood samples from non-COPD subjects recruited consecutively in order to avoid selection bias. Exclusion criteria included a previous diagnosis of acute myocardial infarction, angina, congestive heart failure, cancer, hepatic cirrhosis, chronic renal failure, rheumatoid arthritis or any other systemic inflammatory disease. In addition, we identified a control group of non-COPD subjects after applying the same comorbidity exclusion criteria and specific exclusion criteria of any respiratory symptoms as per the European Coal and Steel Community (ECSC) questionnaire and regularly prescribed medications.<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">7</span></a><a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a> illustrates our cohort.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Procedures</span><p id="par0030" class="elsevierStylePara elsevierViewall">At each study center, lung function tests were performed using the same equipment according to the current recommendations.<a class="elsevierStyleCrossRef" href="#bib0210"><span class="elsevierStyleSup">8</span></a> Spirometry was performed before and 15–30<span class="elsevierStyleHsp" style=""></span>min after salbutamol inhalation. Baseline dyspnea was assessed by the Modified Medical Research Council (MMRC) scale,<a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">9</span></a> and subjects completed the ECSC questionnaire of respiratory symptoms.<a class="elsevierStyleCrossRef" href="#bib0220"><span class="elsevierStyleSup">10</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">Blood samples were collected using standardized procedures and stored at −80<span class="elsevierStyleHsp" style=""></span>°C before sending for the centralized analysis to a single laboratory (Hospital Clinic, Barcelona, Spain). Plasma levels of TNFα, IL-6 and IL-8 were determined in duplicate with a high sensitivity enzyme-linked immunosorbent assays (Biosource, Nivelles, Belgium). We assessed plasma levels of CRP by the latex-enhanced immunonephelometry (Siemens, Dublin, Ireland), AAT by a particle-enhanced immunonephelometry (Siemens, Marburg, Germany), albumin by the bromocresol green method (Siemens, Dublin, Ireland) and fibrinogen by using a coagulation analyzer (Roche, Manheim, Germany). Specific details about the analytic procedures described elsewhere.<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">7</span></a></p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Statistical analysis</span><p id="par0040" class="elsevierStylePara elsevierViewall">Data analysis performed using R, a free software environment for statistical computing and graphics. Statistical significance between subject categories with regard to demographic characteristics and laboratory values was analyzed with ANOVA. Specific pairwise comparisons of subject categories were assessed with the <span class="elsevierStyleItalic">t</span>-test. Least squares linear regression was applied to assess the associations of the dependent variables, such as AAT levels and lung function (post-bronchodilator spirometry), with various other clinical parameters as independent variables. Modeling COPD status as a function of AAT levels and other clinical parameters was performed using logistic regression.</p></span></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Results</span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Characteristics of study participants</span><p id="par0045" class="elsevierStylePara elsevierViewall">Out of 3802 participants, 837 (22%) had available plasma levels of AAT. Of them, 303 (36.2%) had COPD diagnosis, 222 (26.5%) had respiratory symptoms but not COPD, and 312 (37.3%) were healthy, with normal spirometry and without respiratory symptoms, considered as a reference group. The mean (SD) age of cohort was 58.0 (11.3) years. The main characteristics of the participants described in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0050" class="elsevierStylePara elsevierViewall">There were more men within the COPD group than in those with respiratory symptoms or healthy (73.6% vs 53.6% and 44.2%, respectively). Moreover, COPD group was older and had more smokers and ex-smokers relative to other groups. BMI was not significantly different among the groups. As expected, lung function was significantly impaired in COPD individuals compared to the healthy reference group, and there was a wide range of COPD severity in our cohort. Although to a lesser degree, lung function was also decreased in individuals with respiratory symptoms compared to the reference group.</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Plasma levels of AAT and other markers of systemic inflammation</span><p id="par0055" class="elsevierStylePara elsevierViewall">In the entire cohort, levels of AAT were 1.51 (0.47)<span class="elsevierStyleHsp" style=""></span>g/L, with no significant differences between men and women. Notably, a subset of cases (57 or 6.8%) exhibited particularly low levels of plasma AAT (below 1<span class="elsevierStyleHsp" style=""></span>g/L): 20 within COPD, 9 within those having respiratory symptoms and 28 within the reference group. Unfortunately, in this cross-sectional study, genotypes of AAT were not determined and therefore the correlation between genotype and low AAT protein levels could not be analyzed. Removing low-AAT cases as outliers did not affect the observations, and these 57 cases were included in the final analysis. When compared to reference group, subjects with respiratory symptoms or COPD showed higher plasma levels of AAT (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001). As illustrated in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>, analysis of other plasma proteins revealed that COPD subjects had significantly higher plasma levels of CRP, IL-6 and fibrinogen but lower albumin concentrations if compared to the reference group. Plasma levels of TNFα were higher in the COPD and respiratory symptoms groups compared to reference, whereas IL-8 did not significantly differ among the groups.</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Plasma AAT levels in relationship to respiratory health and laboratory measures</span><p id="par0060" class="elsevierStylePara elsevierViewall">We next examined the relationship between plasma AAT levels and clinical/laboratory measures. For this, we applied three types of linear regression models: univariate, correcting for CRP, and multivariate. As shown in <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a> and <a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>, plasma AAT levels were significantly affected by cohort (healthy, respiratory symptoms or COPD), smoking status (smokers but not ex-smokers), lung function tests, and levels of CRP, IL-6, IL-8, fibrinogen and albumin, but not by TNFα.</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0065" class="elsevierStylePara elsevierViewall">Levels of AAT were higher in individuals with COPD or with respiratory symptoms compared to the reference group, an effect that persisted after age and CRP correction, as well as in the multivariate model. Age did not show an impact on AAT levels. Plasma levels of CRP, IL-6, IL-8 and albumin were positively associated, whereas levels of fibrinogen were negatively associated with AAT. After correcting for CRP levels, most parameters remained significantly associated with AAT levels with the exception of FEV1 (pre and post-bronchodilators). The multivariate analysis included smoking status; post FEV/FVC, CRP, IL-6, IL-8, fibrinogen and albumin. Even when modeled jointly, each of these parameters contributed significantly to the multivariate model. This implies that there is an independent relationship of each of these factors to plasma AAT levels.</p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">The relationship between AAT levels and measures of airway obstruction</span><p id="par0070" class="elsevierStylePara elsevierViewall">We also examined whether our data above support the relationship between plasma AAT levels and lung function. To do this, we modeled lung function measures, FEV1 and FEV1/FVC, as a function of AAT and other relevant analytics in both univariate and multivariate models (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>). In the univariate model, FEV1 was significantly and inversely associated with AAT levels, but the effect was weaker relative to factors like sex, BMI and smoking status. When combining these terms in a multivariate model, the above independent effect of AAT was diminished to non-significant level (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.32). However, the association between plasma AAT levels and lung function, as measured by FEV1/FVC ratio, was more robust. Here the inverse association was stronger and remained independently significant even when correcting for other associated factors such as age, sex, smoking status, CRP, TNFα, fibrinogen and albumin. Incidental to the associations of AAT with lung function, we also observe significant decreases in lung function with increased age, smoking, BMI, and CRP. Lung function (FEV1) was positively associated with being female and albumin.</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><p id="par0075" class="elsevierStylePara elsevierViewall">A number of outliers with a high AAT level and high FEV1/FVC (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>), allows suggesting that responders with high AAT may actually be protected from severe COPD when adjusting for smoking and age. Therefore, only for individuals with high AAT levels, we investigated the associations between AAT and FEV1/FVC. We were unable to observe any indications of protection although the low numbers of cases available leaves us underpowered for any conclusive statements.</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Dose response relationship between smoke and AAT level</span><p id="par0080" class="elsevierStylePara elsevierViewall">We have explored whether there is a dose response relationship between smoke and AAT level. By using AAT levels and smoking status as an interaction term in the model, we observed no significant interactions in this cohort. However, we observed for the cohort as a whole, that pack-years were associated with decreased lung function in our multivariate model (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>3.3 E10−7). When used in an interaction term with AAT, we also observed that this interaction was significant (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.06 for FEV1 and 0.009 for FEV/FVC).</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">COPD as a function of plasma AAT levels: binomial logistic regression analysis</span><p id="par0085" class="elsevierStylePara elsevierViewall">Based on the findings above, we were interested in the association of AAT levels with COPD in the context of the other measured clinical variables. To this end, we modeled COPD diagnosis as a function of plasma AAT levels and other measured parameters using binomial logistic regression (<a class="elsevierStyleCrossRef" href="#tbl0020">Table 4</a>). The risk for COPD significantly increased with higher AAT levels in both the univariate and multivariate models, with odds ratios of 1.8 and 1.5, respectively. The univariate model demonstrated that sex, smoking status and CRP levels were associated with COPD. In the multivariate model, these parameters continued to be associated with COPD probability, demonstrating that they act independently. Similarly, we looked at the AAT levels as a risk for respiratory symptoms. Here, we did not observe a significant association with AAT after accounting for other factors, such as smoking status, TNFα, IL-8, and IL-6. Herein smoking status appears to be a strongest risk factor for respiratory symptoms in a non-COPD population.</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia></span></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Discussion</span><p id="par0090" class="elsevierStylePara elsevierViewall">The present study includes Spanish population-based cohort of 837 participants with measured plasma levels of AAT and their detailed characterization, which allows investigating factors associated with circulating AAT, as well as the association of the AAT levels with health indicators of the respiratory system. Importantly, based on CRP measurements we were able to control for systemic inflammation, as a potential confounder.<a class="elsevierStyleCrossRef" href="#bib0225"><span class="elsevierStyleSup">11</span></a></p><p id="par0095" class="elsevierStylePara elsevierViewall">Although determined AAT levels were within the normal reference range [mean (SD) 1.51 (0.47)<span class="elsevierStyleHsp" style=""></span>g/L], participants with stable COPD or with respiratory symptoms showed 8.4% and 9.8% higher levels of plasma AAT than healthy participants [1.43 (0.47)<span class="elsevierStyleHsp" style=""></span>g/L], a finding which was statistically significant and persisted after correction for age and CRP. Results from both the univariate and multivariate models revealed that the risk for COPD was significantly associated with higher circulating levels of AAT. This relationship remained significant even after correction for other factors associated with COPD, such as age, sex, smoking status, CRP, TNFα, fibrinogen and albumin. In fact, we did not observe a significant association between plasma levels of AAT and respiratory symptoms. Herein, smoking status appears to be the strongest risk factor for respiratory symptoms in non-COPD subjects.</p><p id="par0100" class="elsevierStylePara elsevierViewall">Our present findings are in line with those of a Copenhagen General Population study demonstrating that elevated plasma AAT levels were associated with COPD and increased risk of exacerbations.<a class="elsevierStyleCrossRef" href="#bib0230"><span class="elsevierStyleSup">12</span></a> Similarly the epidemiologic study published by Thomsen et al.<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">13</span></a> found higher plasma levels of AAT in never smokers with COPD than in never smokers without COPD. Furthermore, in small cohorts, others and ourselves previously reported higher serum levels of AAT in COPD patients than in controls, independent of genetic AAT-variant.<a class="elsevierStyleCrossRefs" href="#bib0240"><span class="elsevierStyleSup">14,15</span></a> Altogether, previous and our current results provide evidence that higher levels of AAT are associated with COPD.</p><p id="par0105" class="elsevierStylePara elsevierViewall">It is important to point out that in the population-based Swiss SAPALDIA cohort, circulating AAT levels were inversely correlated with FEV1, but only in the absence of CRP adjustment.<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">16</span></a> Accordingly, in our study FEV1 was also significantly and inversely associated with AAT levels, but only without adjustment for other factors like CRP, sex, BMI, and smoking status. However, the negative association between plasma AAT levels and lung function, as measured by FEV1/FVC ratio, was stronger and remained independently significant after adjusting for other associated factors, such as sex, smoking status, CRP, TNFα, fibrinogen and albumin. The ratio of FEV1/FVC is the major determinant of airflow obstruction and the diagnosis of COPD. Therefore, we think that the association between plasma levels of AAT and lung function may depend on the tests performed and used for data analysis. Further studies are required to confirm our suggestion.</p><p id="par0110" class="elsevierStylePara elsevierViewall">COPD is chronic inflammatory disease. Several studies proposed that elevated circulating inflammatory markers, such as CRP, fibrinogen and inflammatory cytokines (TNFα, IL-6, and IL-8) predict morbidity and mortality of patients with COPD.<a class="elsevierStyleCrossRefs" href="#bib0255"><span class="elsevierStyleSup">17,18</span></a> Specifically CRP, a clinical indicator of inflammation,<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">19</span></a> has repeatedly been recommended as a useful predictor of clinical outcomes in patients with COPD.<a class="elsevierStyleCrossRefs" href="#bib0270"><span class="elsevierStyleSup">20–22</span></a> Large prospective studies following healthy people for up to 20 years found that a chronically elevated CRP is associated with a progressive loss of lung function and a greater risk of COPD.<a class="elsevierStyleCrossRefs" href="#bib0285"><span class="elsevierStyleSup">23,24</span></a> A recent study by Bradford et al. found a strong association between IL-6 and COPD status, airflow limitation and emphysema progression.<a class="elsevierStyleCrossRef" href="#bib0295"><span class="elsevierStyleSup">25</span></a></p><p id="par0115" class="elsevierStylePara elsevierViewall">By using the univariate and multivariate models, we found that the risk for COPD significantly increased with higher levels of AAT. In the multivariate model, we also found that sex, smoking status and CRP levels were associated with having COPD, suggesting that they act independently. Similar to CRP or other acute phase proteins, the synthesis of AAT regulated through the action of pro-inflammatory cytokines, specifically IL-6.<a class="elsevierStyleCrossRef" href="#bib0300"><span class="elsevierStyleSup">26</span></a> Therefore, in parallel to increased IL-6 and CRP levels; the low-grade upregulation of AAT in stable COPD may also be useful as a long-term predictor of future outcomes.</p><p id="par0120" class="elsevierStylePara elsevierViewall">The above-mentioned results emphasize that COPD is associated with low-grade systemic inflammation and that circulating cytokines and acute-phase proteins function adversely by maintaining activation of innate immune hyper-responsiveness in the circulation as well as in the lungs. The systemic inflammation in COPD may also explain, at least in part, extra-pulmonary manifestations.<a class="elsevierStyleCrossRef" href="#bib0305"><span class="elsevierStyleSup">27</span></a></p><p id="par0125" class="elsevierStylePara elsevierViewall">Our study has some strengths and limitation. The strengths include the sample size, population-based design, and the detailed characterization of the participants, which allowed us to investigate factors associated with circulating AAT levels as well as the association of the AAT with lung function and COPD. The limitations to be considered are that (i) biomarkers were assessed at only a single time point and thus we could not assess their fluctuation during the course of the disease, (ii) the genotypes of AAT were not determined, and (iii) although significant, the differences in AAT levels between groups were of small magnitude.</p><p id="par0130" class="elsevierStylePara elsevierViewall">We believe that combining information from AAT levels and other acute phase reactants may improve the prediction of risk and/or progression in COPD. It may also help to explain controversies as to whether -systemic inflammation in COPD represents ‘spill over’ from the lung inflammation or is a chronic systemic process.<a class="elsevierStyleCrossRef" href="#bib0310"><span class="elsevierStyleSup">28</span></a> According to recently reported mouse model, the liver may amplify innate immune responsiveness in the lungs after bacterial infection. This latter seems to depend on increased release of IL-6 by alveolar macrophages along with other acute-phase proteins.<a class="elsevierStyleCrossRef" href="#bib0315"><span class="elsevierStyleSup">29</span></a> The liver is a main organ producing and releasing into the circulation acute phase proteins, including AAT and CRP. Different studies demonstrated that activated lung epithelial cells, alveolar macrophages and granulocytes also contribute to the pool of circulating AAT. Whether higher plasma levels of AAT in patients with COPD mirror ‘spill over’ from the lungs or increased release by the liver, we cannot yet answer. Inflammatory process initiated in the lung or elsewhere, may lead to the injury in the alveolar space.<a class="elsevierStyleCrossRef" href="#bib0320"><span class="elsevierStyleSup">30</span></a> In support, results from a Norwegian general population study revealed that increased levels of AAT were associated with a decrease in lung diffusion capacity.<a class="elsevierStyleCrossRef" href="#bib0325"><span class="elsevierStyleSup">31</span></a> Further studies would be necessary to confirm our results and elucidate the source of increased plasma AAT in COPD. Finally, the interest in AAT as a prognostic marker may help to increase the determinations of this protein in COPD and eventually reduce the under diagnosis of the AAT deficiency.<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">32</span></a></p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0140">Conclusion</span><p id="par0135" class="elsevierStylePara elsevierViewall">There is a considerable inter-individual variation in the circulating levels of AAT, and there is no doubt that this plays an important role during health and diseases.<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">1</span></a> Nevertheless, the variability of plasma AAT levels in population-based studies and the possible incorporation of this variability in disease risk assessment remain largely unexplored. A large body of evidence shows that the degree of risk for COPD inversely relates to the plasma level of AAT according to the AAT genotypes: NullNull<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>ZZ<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>SZ<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>MZ.<a class="elsevierStyleCrossRefs" href="#bib0335"><span class="elsevierStyleSup">33,34</span></a> Our study confirms that increased circulating levels of AAT, similarly to CRP, IL-6 and other putative markers of systemic inflammation, is an important feature of COPD. Hence, determination of AAT concentrations can be an important diagnostic and/or monitoring test not only for people with suspected inherited AAT deficiency, but also for a general population with and- without COPD.</p></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0145">Conflicts of interest</span><p id="par0140" class="elsevierStylePara elsevierViewall">Miriam Barrecheguren has received speaker fees from Grifols, Menarini, and consulting fees from Novartis and Gebro Pharma, unrelated to this manuscript. Marc Miravitlles has received speaker or consulting fees from AstraZeneca, Bial, Boehringer Ingelheim, Chiesi, Cipla, CSL Behring, Laboratorios Esteve, Ferrer, Gebro Pharma, GlaxoSmithKline, Grifols, Menarini, Mereo Biopharma, Novartis, pH Pharma, Rovi, TEVA, Verona Pharma and Zambon, and research grants from GlaxoSmithKline and Grifols, unrelated to this manuscript.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:13 [ 0 => array:3 [ "identificador" => "xres1364503" "titulo" => "Graphical abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:3 [ "identificador" => "xres1364504" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0010" "titulo" => "Background" ] 1 => array:2 [ "identificador" => "abst0015" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0020" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0025" "titulo" => "Conclusion" ] ] ] 2 => array:2 [ "identificador" => "xpalclavsec1254375" "titulo" => "Keywords" ] 3 => array:3 [ "identificador" => "xres1364502" "titulo" => "Resumen" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0030" "titulo" => "Introducción" ] 1 => array:2 [ "identificador" => "abst0035" "titulo" => "Métodos" ] 2 => array:2 [ "identificador" => "abst0040" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0045" "titulo" => "Conclusión" ] ] ] 4 => array:2 [ "identificador" => "xpalclavsec1254374" "titulo" => "Palabras clave" ] 5 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 6 => array:3 [ "identificador" => "sec0010" "titulo" => "Methods" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Design of the study" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Study participants" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Procedures" ] 3 => array:2 [ "identificador" => "sec0030" "titulo" => "Statistical analysis" ] ] ] 7 => array:3 [ "identificador" => "sec0035" "titulo" => "Results" "secciones" => array:6 [ 0 => array:2 [ "identificador" => "sec0040" "titulo" => "Characteristics of study participants" ] 1 => array:2 [ "identificador" => "sec0045" "titulo" => "Plasma levels of AAT and other markers of systemic inflammation" ] 2 => array:2 [ "identificador" => "sec0050" "titulo" => "Plasma AAT levels in relationship to respiratory health and laboratory measures" ] 3 => array:2 [ "identificador" => "sec0055" "titulo" => "The relationship between AAT levels and measures of airway obstruction" ] 4 => array:2 [ "identificador" => "sec0060" "titulo" => "Dose response relationship between smoke and AAT level" ] 5 => array:2 [ "identificador" => "sec0065" "titulo" => "COPD as a function of plasma AAT levels: binomial logistic regression analysis" ] ] ] 8 => array:2 [ "identificador" => "sec0070" "titulo" => "Discussion" ] 9 => array:2 [ "identificador" => "sec0075" "titulo" => "Conclusion" ] 10 => array:2 [